ArticleAmerican journal of translational research2022
Circular RNA FOXO3 regulates endometrial carcinoma progression through the microRNA-29a-3p/HDAC4 axis.
Article in American journal of translational research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 2 citations in OpenAlex.
- Building a Hand-Curated ceRNET for Endometrial Cancer, Striving for Clinical as Well as Medicolegal Soundness: A Systematic Review.Non-coding RNA · 2025Review
- Research progress of circular RNA FOXO3 in diseases (review).Global medical genetics · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previous studies determined that circular RNA FOXO3 (circ_FOXO3) plays a critical role in tumorigenesis. The definite molecular mechanism of cir_FOXO3 in endometrial carcinoma (EC), nevertheless, had not been fully explored. Circ_FOXO3 expression was determined using quantitative real-time polymerase chain reaction in human EC tissues and cell lines, whereas small interfering RNAs were used to specifically silence circ_FOXO3 expression in cultured EC cells. The cell counting kit-8 assay was employed to determine the effect of ectopic circ_FOXO3 expression on cell viability. Cell proliferation and apoptosis were evaluated by flow cytometry. Further, migration and invasion of EC cells were characterized using the Transwell assay. The interaction between microRNA (miR)-29a-3p and circ_FOXO3/histone deacetylase 4 (HDAC4) was validated using dual luciferase reporter assay. Additionally, qRT-PCR and WB were employed to determine HDAC4 levels. We found that circ_FOXO3 was highly expressed in EC cells and tissues. Moreover, suppressing circ_FOXO3 expression abrogated EC by regulating cell proliferation, apoptosis, migration, and invasion. Furthermore, circ_FOXO3 could act as a sponge for miR-29a-3p, and inhibition of miR-29a-3p expression reversed the effects of circ_FOXO3 suppression on EC progression. Overexpression of miR-29a-3p inhibited EC cell growth, migration, and invasion through the regulation of HDAC4, as it is a target of miR-29a-3p. In conclusion, circ_FOXO3 promotes EC progression by sponging miR-29a-3p and upregulating HDAC4, making it a promising therapeutic target in EC.
Indexed as
Identifiers
36628205PMC9827307W4315620660What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.